Accuray (Accuray) ROCE % : -8.59% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Accuray ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Accuray's annualized ROCE % for the quarter that ended in Dec. 2023 was -8.59%.

Accuray ROCE % Historical Data

The historical data trend for Accuray's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray ROCE % Chart

Accuray Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

0.33

8.57

4.14

2.22

1.41

Accuray Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															2.61	5.42	1.45	2.71	-8.59

Accuray ROCE % Calculation

Accuray's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	3.844	/	( ( (472.849 - 208.858)	+	(479.214 - 198.637) )	/ 2 )
	=	3.844	/	( (263.991	+	280.577)	/ 2 )
	=	3.844	/	272.284
	=	1.41 %

Accuray's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-23.284	/	( ( (476.83 - 201.449)	+	(476.35 - 209.306) )	/ 2 )
	=	-23.284	/	( ( 275.381	+	267.044 )	/ 2 )
	=	-23.284	/	271.2125
	=	-8.59 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Accuray (NAS:ARAY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Accuray ROCE % Related Terms

Thank you for viewing the detailed overview of Accuray's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accuray (Accuray) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XEJ:Germany

Address

1240 Deming Way, Madison, WI, USA, 53717

Website

https://www.accuray.com

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Executives

Gina Corradetti	officer: VP, Corporate Controller	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz	officer: SVP Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew	officer: SVP and General Counsel	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke	officer: SVP, Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter	officer: SVP & Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine	officer: SVP, Chief Admin Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge	officer: Senior VP Global Operations	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill	director	VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green	officer: Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba	officer: VP, Chief Accounting Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott	director	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine	officer: President & CEO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters	director
Shigeyuki Hamamatsu	officer: VP, Finance and CAO	1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043